Oct 18 (Reuters) – NuCana PLC: * NUCANA PRESENTS ENCOURAGING DATA ON NUC-7738 IN COMBINATION WITH PD-1 INHIBITORS USING PRIMARY PATIENT-DERIVED ORGANOIDS AND AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES AT THE ESMO CONGRESS 2025 * NUCANA PLC – REGULATORS APPROVE STUDY EXPANSION FOR 28 MORE PATIENTS * NUCANA PLC – DATA TO DATE FROM NUTIDE:701 SHOWS FAVORABLE SAFETY AND TUMOR REDUCTION Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
RAFAH CROSSING RE-OPENING WILL ALLOW PALESTINIANS RESIDING IN EGYPT TO RETURN TO GAZA - PALESTINIAN…
(Adds Maresca quotes, details) NOTTINGHAM, England, Oct 18 (Reuters) - Nottingham Forest sacked manager Ange…
By Raphael Satter WASHINGTON (Reuters) -A U.S. court has ordered Israel's NSO Group to stop…
(Reuters) -French luxury group Kering is in advanced talks to sell its beauty division to…
By Raphael Satter WASHINGTON (Reuters) -A U.S. court has ordered Israel's NSO Group to stop…
By Paul Sandle, Michael Kahn, Byron Kaye and Dawn Chmielewski LONDON/PRAGUE/SYDNEY/LOS ANGELES (Reuters) -"Star Wars:…